A controlled clinical trial of treatment with ALG in established rejection of renal allografts.

A controlled clinical investigation of the effect of equine anti-human-lymphocyte globulin (ALG) on established rejection after transplantation has been carried out in a group of 31 patients. Compared with a control group, the treated group showed a significantly positive effect of ALG in the form of a faster reversal of rejection episodes (p less than 0.05). Leucocytes, lymphocytes, erythrocytes, thrombocytes and immunoglobulins were unaffected by the treatment, but there were signs of a complement-consuming process and an influence on blast transformation tests. No rise in antibody titre against equine globulin was seen.